ArticlePloS one2010
Comparative genomics of Gardnerella vaginalis strains reveals substantial differences in metabolic and virulence potential.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The vaginal microbiota: what have we learned after a decade of molecular characterization?PloS one · 2014Pooled it
- Comparative proteomics reveal striking differences in biofilm formation and virulence potential ofJournal of bacteriology · 2026Article
- Genitourinary microbiota in older women: a persistent knowledge gap that limits clinical and research progress.Infection and immunity · 2026Review
- Rethinking Vaginal Microbiome Resilience: A Conceptual Multi-Omic Framework.Microorganisms · 2026Review
- A syntenic pangenome of Gardnerella reveals novel plasmids and phage, taxonomic boundaries, and species-level stratification of metabolic and virulence potential.Nature communications · 2026Article
- The proteinaceous biofilm ofBiofilm · 2026Article
- Genetic transformation ofInfection and immunity · 2025Article
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Metronidazole response profiles of Gardnerella species are congruent with phylogenetic and comparative genomic analyses.Genome medicine · 2025Article
- Impact of bacterial vaginosis on sexually transmitted viral infections: a bacterial point of view.FEMS microbiology reviews · 2025Review
- Combatting antibiotic resistance in Gardnerella vaginalis: A comparative in silico investigation for drug target identification.PloS one · 2025Article
- Article
- Phase variable colony variants are conserved acrossmSphere · 2024Article
- Article
- Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms.Scientific reports · 2024Article
- Sexual transmission of urogenital bacteria: whole metagenome sequencing evidence from a sexual network study.mSphere · 2024Article
- Vaginal dysbiosis and the potential of vaginal microbiome-directed therapeutics.Frontiers in microbiomes · 2024Review
- Integrating compositional and functional content to describe vaginal microbiomes in health and disease.Microbiome · 2023Article
- Under conditions closely mimicking vaginal fluid,Microbiology (Reading, England) · 2023Article
- Evaluation of vaginal microbiome equilibrium states identifies microbial parameters linked to resilience after menses and antibiotic therapy.PLoS computational biology · 2023Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundGardnerella vaginalis is described as a common vaginal bacterial species whose presence correlates strongly with bacterial vaginosis (BV). Here we report the genome sequencing and comparative analyses of three strains of G. vaginalis. Strains 317 (ATCC 14019) and 594 (ATCC 14018) were isolated from the vaginal tracts of women with symptomatic BV, while Strain 409-05 was isolated from a healthy, asymptomatic individual with a Nugent score of 9. PRINCIPAL
findingsSubstantial genomic rearrangement and heterogeneity were observed that appeared to have resulted from both mobile elements and substantial lateral gene transfer. These genomic differences translated to differences in metabolic potential. All strains are equipped with significant virulence potential, including genes encoding the previously described vaginolysin, pili for cytoadhesion, EPS biosynthetic genes for biofilm formation, and antimicrobial resistance systems, We also observed systems promoting multi-drug and lantibiotic extrusion. All G. vaginalis strains possess a large number of genes that may enhance their ability to compete with and exclude other vaginal colonists. These include up to six toxin-antitoxin systems and up to nine additional antitoxins lacking cognate toxins, several of which are clustered within each genome. All strains encode bacteriocidal toxins, including two lysozyme-like toxins produced uniquely by strain 409-05. Interestingly, the BV isolates encode numerous proteins not found in strain 409-05 that likely increase their pathogenic potential. These include enzymes enabling mucin degradation, a trait previously described to strongly correlate with BV, although commonly attributed to non-G. vaginalis species.
conclusionsCollectively, our results indicate that all three strains are able to thrive in vaginal environments, and therein the BV isolates are capable of occupying a niche that is unique from 409-05. Each strain has significant virulence potential, although genomic and metabolic differences, such as the ability to degrade mucin, indicate that the detection of G. vaginalis in the vaginal tract provides only partial information on the physiological potential of the organism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.